Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

for
Advanced Solid Tumor
Location: Houston TX
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Sex: All

Age: 18+

Code: NCT05119933

Phase 1, Phase 2, Recruiting

A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

for
Metastatic Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06693687

Recruiting

Writing Intervention With Adolescents and Young Adults With Cancer

for
Cancer Patients, Communication Research
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 15 - 25

Code: NCT05975333

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

for
Advanced Cancer, Metastatic Cancer
Location: Durham NC, Miami FL
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06174987

Phase 3, Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Boston MA, Houston TX
Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All

Age: 18+

Code: NCT06641908

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Myeloproliferative Neoplasms (MPNs) Patient Registry

for
Primary Myelofibrosis, Polycythemia Vera,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 0+

Code: NCT02760238

Recruiting

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

for
Metastatic Malignant Neoplasm in the Brain,
Location: Philadelphia PA
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Sex: All

Age: 18+

Code: NCT03184038

Recruiting

Evaluation of Adults With Endocrine and Metabolic-Related Conditions

for
Endocrine Diseases
Location: Bethesda MD
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Sex: All

Age: 18 - 70+

Code: NCT02830308

Recruiting

AIMS Cancer Outcomes Study

for
Neoplasms, Neoplasm Malignant, Advanced Cancer,
Location: Seattle WA
Sponsor: Advanced Integrative Medical Science Institute

Sex: All

Age: 0+

Code: NCT04495790

Recruiting

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

for
Malignant Neoplasm
Location: Albuquerque NM
Sponsor: New Mexico Cancer Research Alliance

Sex: All

Age: 18+

Code: NCT06207864

Recruiting

Skincare Products and Environmental Health

for
Gynecomastia, Endocrine System Diseases
Location: Franklin TN
Sponsor: Nutraceuticals Research Institute

Sex: All

Age: 2 - 15

Code: NCT04836364

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

for
Malignant Neoplasms, Hereditary Neoplastic Syndromes,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 2+

Code: NCT00026884

Recruiting

The Intersection of Oncology Care and Worker Well-Being

for
Solid Tumor
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: Male

Age: 21 - 70

Code: NCT05250284

Recruiting

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

for
Solid Tumors
Location: Fairfax VA, Grand Rapids MI, Minneapolis MN, Houston TX,
Sponsor: Adcentrx Therapeutics

Sex: All

Age: 18+

Code: NCT06710379

Phase 1, Recruiting

First in Human, Dose Escalation Study of AN4005

for
Advanced Solid Tumor, Advanced Lymphoma
Location: The Bronx NY, Hackensack NJ, Fairfax VA, Greenville SC
Sponsor: Adlai Nortye Biopharma Co., Ltd.

Sex: All

Age: 18+

Code: NCT04999384

Phase 1, Recruiting

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

for
Pediatric Brain Tumor, Pediatric Solid Tumor
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 6 - 21

Code: NCT05521984

Phase 1, Recruiting

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

for
Gynecologic Cancer, Carcinoma, Uterine Cancer,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: Female

Age: 18+

Code: NCT05559879

Phase 1, Phase 2, Recruiting

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

for
Solid Tumor
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All

Age: 18+

Code: NCT05585684

Recruiting

A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

for
Pan-cancer
Location: Sioux Falls SD
Sponsor: Avera McKennan Hospital & University Health Center

Sex: All

Age: 0+

Code: NCT05308784

Recruiting

Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type

for
Cancer, Smoking
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT06484179

Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial